04-10-2019 / Anna Pasetto, Ph.D. Assistant Professor, Karolinska Institutet
HCC is a major cause of cancer-related death in the world and the current available treatments are effective only at an early stage. For advanced HCC the only approved therapy is Sorafenib (a multi kinase inhibitor) which has low response rate (about 3%).
Learn More
05-15-2018 / Ruina He and Amy Mendenhall
Cancer immunotherapy has emerged as an exciting new approach to cancer treatment because of its specificity, adaptability and durability.
Learn More
08-27-2017 / Liyan Pang, Ph.D.
Are you struggling with the amount and/or purity of your recombinant protein? Attend this online seminar for solutions to the challenges in recombinant protein expression & purification.
Learn More
08-15-2017 / XinPo Jiang, Ph.D. and Amy Mendenhall, Ph.D.
Development of therapeutic antibodies against immune checkpoints for the treatment of melanoma and other cancers is gaining momentum among academia and the pharmaceutical industry.
Learn More
10-06-2016 / Liusong Yin, Ph.D.
Therapeutic antibody drugs have recently experienced explosive growth. Within oncology research alone, 14 therapeutic antibody drugs received FDA
Learn More
07-21-2015 / James Mixson, University of Maryland, School of Medicine
Conducting research in cancer therapeutics? Have you considered using cell/tumor penetrating peptides?
Learn More